Cargando…

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains t...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Chiaki, Kiyota, Naomi, Imamura, Yoshinori, Goto, Hideaki, Suto, Hirotaka, Chayahara, Naoko, Toyoda, Masanori, Ito, Yasuhiro, Miya, Akihiro, Miyauchi, Akira, Teshima, Masanori, Otsuki, Naoki, Nibu, Ken-ichi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/
https://www.ncbi.nlm.nih.gov/pubmed/34307122
http://dx.doi.org/10.3389/fonc.2021.638123
_version_ 1783726118407241728
author Suzuki, Chiaki
Kiyota, Naomi
Imamura, Yoshinori
Goto, Hideaki
Suto, Hirotaka
Chayahara, Naoko
Toyoda, Masanori
Ito, Yasuhiro
Miya, Akihiro
Miyauchi, Akira
Teshima, Masanori
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
author_facet Suzuki, Chiaki
Kiyota, Naomi
Imamura, Yoshinori
Goto, Hideaki
Suto, Hirotaka
Chayahara, Naoko
Toyoda, Masanori
Ito, Yasuhiro
Miya, Akihiro
Miyauchi, Akira
Teshima, Masanori
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
author_sort Suzuki, Chiaki
collection PubMed
description BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. METHODS: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. RESULTS: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. CONCLUSIONS: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib.
format Online
Article
Text
id pubmed-8298753
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82987532021-07-24 Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Suzuki, Chiaki Kiyota, Naomi Imamura, Yoshinori Goto, Hideaki Suto, Hirotaka Chayahara, Naoko Toyoda, Masanori Ito, Yasuhiro Miya, Akihiro Miyauchi, Akira Teshima, Masanori Otsuki, Naoki Nibu, Ken-ichi Minami, Hironobu Front Oncol Oncology BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. METHODS: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. RESULTS: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. CONCLUSIONS: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib. Frontiers Media S.A. 2021-07-08 /pmc/articles/PMC8298753/ /pubmed/34307122 http://dx.doi.org/10.3389/fonc.2021.638123 Text en Copyright © 2021 Suzuki, Kiyota, Imamura, Goto, Suto, Chayahara, Toyoda, Ito, Miya, Miyauchi, Teshima, Otsuki, Nibu and Minami https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Suzuki, Chiaki
Kiyota, Naomi
Imamura, Yoshinori
Goto, Hideaki
Suto, Hirotaka
Chayahara, Naoko
Toyoda, Masanori
Ito, Yasuhiro
Miya, Akihiro
Miyauchi, Akira
Teshima, Masanori
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
title Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
title_full Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
title_fullStr Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
title_full_unstemmed Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
title_short Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
title_sort exploratory analysis to predict optimal tumor burden for starting lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/
https://www.ncbi.nlm.nih.gov/pubmed/34307122
http://dx.doi.org/10.3389/fonc.2021.638123
work_keys_str_mv AT suzukichiaki exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT kiyotanaomi exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT imamurayoshinori exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT gotohideaki exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT sutohirotaka exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT chayaharanaoko exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT toyodamasanori exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT itoyasuhiro exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT miyaakihiro exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT miyauchiakira exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT teshimamasanori exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT otsukinaoki exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT nibukenichi exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer
AT minamihironobu exploratoryanalysistopredictoptimaltumorburdenforstartinglenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancer